EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Amitriptyline use in individuals with KCNQ2/3 gain‐of‐function variants: A retrospective cohort study

Matthias De Wachter iD, Charissa Millevert, Joost Nicolai, Elisabeth Cats, Gerhard Kluger, Mathieu Milh iD, Robin Cloarec, Steffen Syrbe, Katrijn Arts, Katrien Jansen, Magdalena Krygier iD, Robert Smigiel und 7 weitere

Epilepsia · 2025

DOI: 10.1111/epi.18310 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, 2025. Verfasst von Matthias De Wachter und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium. Hauptthemen laut MEDLINE: Amitriptyline, Gain of Function Mutation, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Heterozygous gain‐of‐function (GOF) variants in KCNQ2 and KCNQ3 , encoding the voltage‐gated potassium channel subunits Kv7.2 and Kv7.3, lead to neurodevelopmental disorders for which no established treatments are available. Amitriptyline, an antidepressant, blocks Kv7.2/Kv7.3 and has previously been reported to be effective in a single individual with a KCNQ2 GOF variant. We designed a retrospective, single‐arm, multicenter study to investigate the effects of amitriptyline in a real‐world setting.

Methods

We used a 7‐point Likert scale to measure seizure frequency, clinical examination, motor function, alertness, skill acquisition, communication, mood, behavior, self‐care, sleep, tiredness, and electroencephalogram at baseline, after a minimum of 6 weeks of intervention, and, if applicable, after discontinuation. Adverse events were assessed in all participants, and the effectiveness of the treatment was evaluated in 11 individuals who received a minimum dosage of .5 mg/kg/day for at least 6 weeks. Data were collected from October 2023 to August 2024.

Results

Thirteen individuals, eight with a pathogenic KCNQ2 GOF variant and five with a pathogenic KCNQ3 GOF variant, were included. Nine were female, and the median age at start of amitriptyline was 7.1 years (range = 1.5–20 years). Eleven individuals received a minimum dosage of .5 mg/kg/day for at least 6 weeks. The median dosage of amitriptyline administered was 1 mg/kg/day, with a median treatment duration of 29 weeks. Although amitriptyline was ineffective in two individuals (18%), eight (72%) demonstrated at least minimal improvement in two or more domains, with improvements in alertness and communication being the most frequently reported. In those with reported improvements, amitriptyline was discontinued in four individuals, but continued improvements were seen, to the same or greater extent compared to treatment. The remaining five individuals are on continued treatment because of perceived benefits. Significance Overall, the effect of amitriptyline remains unclear, and formal n ‐of‐1 trials are needed to investigate the precise effects of amitriptyline in KCNQ GOF‐related neurodevelopmental disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmitriptylineGain of Function MutationKCNQ2 Potassium ChannelKCNQ3 Potassium ChannelAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultCohort StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

KCNQ2KCNQ3neurodevelopmental delayn‐of‐1 trialprecision medicine

Substanzen

AmitriptylineKCNQ2 Potassium ChannelKCNQ2 protein, humanKCNQ3 Potassium ChannelKCNQ3 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center (EpiCARE member), Dianalund, Denmark.
  • Department of Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • Vlaams Instituut voor Biotechnologie (VIB) Center for Molecular Neurology, Antwerp, Belgium.
  • Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Gelre Hospitals, Apeldoorn, the Netherlands.

ORCID-Profile: Matthias De Wachter, Mathieu Milh, Magdalena Krygier, Stephane Auvin, Cathrine Elisabeth Gjerulfsen, Rikke S Møller, Allan Bayat, Sarah Weckhuysen

Zitieren

APA

De Wachter, M., Millevert, C., Nicolai, J., Cats, E., Kluger, G., Milh, M., Cloarec, R., Syrbe, S., Arts, K., Jansen, K., Krygier, M., Smigiel, R., Auvin, S., Olofson, K., Gjerulfsen, C. E., Ceulemans, B., Møller, R. S., Bayat, A., & Weckhuysen, S. (2025). Amitriptyline use in individuals with KCNQ2/3 gain‐of‐function variants: A retrospective cohort study. Epilepsia. https://doi.org/10.1111/epi.18310

Vancouver

De Wachter M, Millevert C, Nicolai J, Cats E, Kluger G, Milh M, et al. Amitriptyline use in individuals with KCNQ2/3 gain‐of‐function variants: A retrospective cohort study. Epilepsia. 2025. doi:10.1111/epi.18310

BibTeX
@article{DeWachter2025,
  author = {De Wachter, Matthias and Millevert, Charissa and Nicolai, Joost and Cats, Elisabeth and Kluger, Gerhard and Milh, Mathieu and Cloarec, Robin and Syrbe, Steffen and Arts, Katrijn and Jansen, Katrien and Krygier, Magdalena and Smigiel, Robert and Auvin, Stephane and Olofson, Kern and Gjerulfsen, Cathrine Elisabeth and Ceulemans, Berten and Møller, Rikke S and Bayat, Allan and Weckhuysen, Sarah},
  title = {Amitriptyline use in individuals with KCNQ2/3 gain‐of‐function variants: A retrospective cohort study},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18310}
}
Kostenlos starten →